NYSE:BAX

New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years

Retrieved on: 
Mercredi, mai 29, 2024
Research, Surgery, Medical Devices, Hospitals, Biotechnology, Health, Pharmaceutical, General Health, Science, Patient, Cardiovascular disease, Doctor of Philosophy, HDX, HF, HDF, Dialysis, HD, Congress, Blood, Baxter International, Kidney, MB, Mortality, MCO, ID, Inflammation, Pharmaceutical industry

The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.

Key Points: 
  • The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.
  • The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia.
  • In the study, 533 patients received high-flux hemodialysis and were compared to 559 patients who received HDx therapy.
  • “It is very exciting to see the results of this four-year study, indicating approximately 25% lower mortality for chronic kidney patients with the use of Baxter’s Theranova dialyzer.

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Retrieved on: 
Mercredi, mai 15, 2024
Baxter International, Patient, Good manufacturing practice, Food, CMOS, FDA, Therapy, Safety, SAN, Complaint, LLP, Lung cancer, Agitation, BLA, Institutional review board, Dementia, GMP, Record, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).
  • Defendants’ failure to disclose Baxter’s true problems relating to its supply chain deceived investors about the Company’s true financial health and earnings.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Eagle Pharmaceuticals, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) against certain of its officers and directors.

Baxter to Present at Jefferies 2024 Global Healthcare Conference

Retrieved on: 
Jeudi, mai 23, 2024
Professional Services, Health, Health Technology, Finance, General Health, Banking, Conference, Baxter International, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024.

Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive

Retrieved on: 
Mercredi, mai 15, 2024
Biotechnology, General Health, Biometrics, Health, Pharmaceutical, Patient, Baxter, Baxter International, Medtech, Sale, Multimedia, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive .

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive .
  • View the full release here: https://www.businesswire.com/news/home/20240515943576/en/
    Baxter announced the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
  • (Graphic: Business Wire)
    The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond.
  • Baxter announced in 2023 plans to create a new Kidney Care company from its Renal Care and Acute Therapies businesses.

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Retrieved on: 
Lundi, mai 13, 2024
Medical Supplies, Women, FDA, Baby, Maternity, Fitness & Nutrition, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Patient, Oleic acid, Route of administration, Risk, Olive oil, Tubing (recreation), Parenteral nutrition, Soybean oil, Chinese, Growth, Baxter International, Malnutrition, U.S. FDA, Dietary supplement

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
  • Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.
  • Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.
  • Over the last several years, clinical practice has shifted away from using 100 percent soybean oil lipid emulsions – which was the standard of care for decades – to mixed lipid emulsions.

Baxter to Present at Bank of America 2024 Health Care Conference

Retrieved on: 
Mardi, mai 7, 2024
Professional Services, Medical Supplies, Health, Other Health, Finance, General Health, Banking, Hospital, Baxter International, Nursing care plan, Patient, Bank, Conference, Medtech, Caregiver

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 3:00 p.m. Pacific Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, August 14, 2024.
  • Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care.

Baxter Declares Quarterly Dividend

Retrieved on: 
Mardi, mai 7, 2024
Medical Supplies, Health, Medical Devices, Health Technology, Pharmaceutical, Optical, Biotechnology, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
  • The dividend is payable on July 1, 2024, to stockholders of record as of May 31, 2024.
  • The indicated annual dividend rate is $1.16 per share of common stock.

Baxter Reports First-Quarter 2024 Results

Retrieved on: 
Jeudi, mai 2, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Sale, FDA, Baxter, Pharmacist, Sodium chloride, Food, Growth, LVP, SYR, Novum, Baxter International, Nursing, Patient, EPS, CDT, BPS, GAAP, Food and Drug Administration, Vasopressin

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
  • Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
  • For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
  • A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Jeudi, avril 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors

Retrieved on: 
Mercredi, avril 10, 2024
Surgery, Medical Devices, Medical Supplies, Hospitals, Health Technology, Practice Management, Biotechnology, Health, General Health, Baxter International, Central Time, Webcast, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.
  • To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information.
  • This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
  • The conference call will be recorded by Baxter and is copyrighted material.